Scilex Holding Company Fair Value Adjustment of Warrants
Scilex Holding Company (SCLX) reported Fair Value Adjustment of Warrants of $300.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-10.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-04-10
- Scilex Holding Company fair value adjustment of warrants for the quarter ending 2024-12-31 was $0.00.
- Scilex Holding Company fair value adjustment of warrants for the quarter ending 2022-09-30 was -$68.40K, a 105.88% decline year-over-year.
- Scilex Holding Company fair value adjustment of warrants for the quarter ending 2022-06-30 was -$2.53M, a 3800.00% decline year-over-year.
- Scilex Holding Company fair value adjustment of warrants for the quarter ending 2022-03-31 was $410.40K.
- Scilex Holding Company fair value adjustment of warrants for fiscal 2025 was $300.00K, a 0.00% change from fiscal 2024.
- Scilex Holding Company fair value adjustment of warrants for fiscal 2024 was $300.00K.
- Scilex Holding Company fair value adjustment of warrants for fiscal 2021 was -$4.38M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 3 month as first filed | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $300.00K 10-K · filed 2026-04-10 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $300.00K 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $300.00K 10-Q · filed 2025-01-17 | ||||
| 2022-09-30 | -$68.40K 10-Q · filed 2022-11-04 | -$2.60M derived: sum of 2 quarters · filed 2022-11-04 | -$2.19M 10-Q · filed 2022-11-04 | -$3.69M derived: sum of 4 quarters · filed 2022-11-04 | |
| 2022-06-30 | -$2.53M 10-Q · filed 2022-08-12 | -$2.12M 10-Q · filed 2022-08-12 | -$3.63M derived: sum of 3 quarters · filed 2022-08-12 | -$2.46M derived: sum of 4 quarters · filed 2022-11-04 | |
| 2022-03-31 | $410.40K 10-Q · filed 2022-05-16 | -$1.09M derived: sum of 2 quarters · filed 2022-05-16 | $68.40K derived: sum of 3 quarters · filed 2022-11-04 | $136.80K derived: sum of 4 quarters · filed 2022-11-04 | |
| 2021-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$342.00K derived: sum of 2 quarters · filed 2022-11-04 | -$273.60K derived: sum of 3 quarters · filed 2022-11-04 | -$4.38M 10-K · filed 2022-02-24 | |
| 2021-09-30 | $1.16M 10-Q · filed 2022-11-04 | $1.23M derived: sum of 2 quarters · filed 2022-11-04 | -$2.87M 10-Q · filed 2022-11-04 | ||
| 2021-06-30 | $68.40K 10-Q · filed 2022-08-12 | -$4.04M 10-Q · filed 2021-08-19 | -$4.04M 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | -$4.10M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |